Pre-existing anti-neuraminidase antibodies are associated with shortened duration of influenza A (H1N1)pdm virus shedding and illness in naturally infected adults.
Influenza causes a substantial burden worldwide, and current seasonal influenza vaccine has suboptimal effectiveness. To develop better, more broadly protective vaccines, a more thorough understanding is needed of how antibodies that target the influenza virus surface antigens, hemagglutinin (HA; including head and stalk regions), and neuraminidase (NA), impact influenza illness and virus transmission. We used a case-ascertained, community-based study of household influenza virus transmission set in Managua, Nicaragua. Using data from 170 RT-PCR-confirmed influenza virus A(H1N1)pdm infections and 45 household members with serologically-confirmed infection, we examined the association of pre-existing NA, hemagglutination inhibiting (HAI), and HA stalk antibody levels and influenza viral shedding and disease duration using accelerated failure time (AFT) models. Among RT-PCR-confirmed infections in adults, pre-existing anti-NA antibody levels of ≥40 were associated with a 69% (95%CI: 34%, 85%) shortened shedding duration (mean: 1.0 vs 3.2 days). NA antibody levels of ≥80 were associated with further shortened shedding and significantly shortened symptom duration (ILI: 82%, 95%CI: 39%, 95%). Among RT-PCR-confirmed infections in children, HAI titers of ≥1:20 were associated with a 32% (95%CI: 13%, 47%) shortened shedding duration (mean: 3.9 vs 6.0 days). Our results suggest that anti-NA antibodies play a large role in reducing influenza illness duration in adults and may impact transmission, most clearly among adults. Neuraminidase should be considered as an additional target in next-generation influenza virus vaccine development.